BALDWIN
PARK, Calif., May 23, 2024
/PRNewswire/ -- StemCyte, a leader in cord blood-based regenerative
therapeutics in Southern
California, is excited to announce the renewal of its
partnership with the California State Umbilical Cord Blood
Collection Program (CA-UCBCP). In collaboration with UC Davis
Health, the CA-UCBCP has helped StemCyte enhance cord blood
collection efforts.
StemCyte's commitment to ethnic diversity in cord blood banking
is unmatched. With thousands of cord blood units banked from
Latino, Asian, and African American communities, StemCyte has been
the primary provider of transplant units through the CA-UCBCP since
2013. The enhanced contract includes additional funding to further
diversify the NMDP National Registry, ensuring individuals of all
racial and ethnic backgrounds can find genetically compatible cord
blood units. Furthermore, StemCyte and UC Davis Health are working
to establish new hospital collection sites in the Palm Springs area and Sacramento later this year.
Dr. Tong-Young Lee, CEO of
StemCyte, shared his enthusiasm about the partnership renewal: "We
are excited to renew our partnership with the CA-UCBCP so that we
may continue to educate and empower expectant mothers and their
families to contribute to life-saving treatments through cord blood
donation. Our strengthened alliance with the CA-UCBCP is a
testament to our unwavering commitment to enhancing racial
diversity in cord blood donations and supporting families facing
serious health challenges."
Since the first umbilical cord blood transplant in 1988,
approximately 60,000 patients globally have benefited from such
procedures for various hematopoietic, immune, and metabolic
disorders. StemCyte has played a pivotal role, supplying over 2,300
cord blood units for transplants, aiding 1 in 26 patients
worldwide. The company's compliance with international quality
standards has garnered the trust of over 350 transplant centers
worldwide, including the top eight transplant centers in
the United States.
In its pursuit for innovation, StemCyte submitted a Biologics
License Application (BLA) for their HPC, Cord Blood product
RegeneCyte® to the FDA in January
2022. This product aims to provide hematopoietic and
immunologic reconstitution in patients with hematopoietic system
disorders as part of unrelated donor transplantation
procedures.
As a trailblazer in regenerative cell therapy, StemCyte offers
both public and private umbilical cord blood banking and is
actively developing new treatments. The company sponsors several
ongoing clinical trials, including Phase II trials using cord blood
for post-COVID syndrome and cord blood-derived mononuclear cells
for spinal cord injury. A Phase II trial for acute ischemic stroke
is also planned for 2024. Compassionate use treatments with HPC,
Cord Blood and umbilical cord mesenchymal stem cells (MSC) have
shown encouraging results in treating conditions such as cerebral
palsy and hypoxic ischemic encephalopathy.
As the company continues to explore innovative regenerative cell
therapy avenues for product development, StemCyte remains committed
to advancing medical science and improving patient outcomes. The
company looks forward to a future where the potential of cord blood
therapies is fully realized, offering new hope and healing to
patients worldwide.
For more information about StemCyte's cord blood and cord tissue
banking services, ongoing clinical trials, or the renewed
partnership with CA-UCBCP, please visit www.stemcyte.com or call
(626) 646-2500.
Contact: research@stemcyte.com
About StemCyte: StemCyte's global headquarters is located in
Baldwin Park, California, with
additional operations in Taiwan
and India. The company has a
unique dual public and private bank, accredited by both AABB and
FACT. StemCyte is dedicated to helping more people worldwide
achieve a better quality of life through the innovative use of cord
blood and related stem cell therapies.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stemcyte-renews-contract-with-the-california-state-umbilical-cord-blood-collection-program-302154427.html
SOURCE StemCyte